Global biotechnology leader CSL Behring (ASX:CSL; USOTC: CSLLY (OTC:CSLLY)) announced the four-year results from the HOPE-B study, confirming the long-term efficacy and safety of HEMGENIX® ...
Some results have been hidden because they may be inaccessible to you